Skip to main content
ACR Convergence 2023 Main banner
Final Program


Schedule at a Glance
Legend
Session Format
In Person
In Person
Livestreamed
Livestreamed
On Demand
On Demand
Back

Lihi Eder, MD, PhD

University of Toronto
Toronto, ON, Canada

Dr. Eder is Clinician-Scientist and staff rheumatologist at the Women’s College Research Institute and Associate Professor of Medicine, University of Toronto, Canada. Dr. Eder has a broad background in rheumatology with specific training and expertise in clinical and genetic epidemiology of psoriatic arthritis and cardiovascular diseases in rheumatic patients. She is Director, University of Toronto, Cardio-Rheumatology Program, an interdisciplinary program that aims to improve the management of cardiovascular morbidities in rheumatic patients by developing novel models of care and through research and educational activities. Dr Eder’s research is supported by grants from national and international agencies including the Canadian Institute of Health Research (CIHR), Canadian Rheumatology Association, The Arthritis Society, and the National Psoriasis Foundation (US). Dr. Eder’s research efforts have resulted in over 140 peer-reviewed publications in medical journals, book chapters, and editorials. She is frequently invited to present the result of her studies at national and international conferences in the fields of rheumatology, dermatology, and cardiology. As a recognized emerging expert in rheumatology, she received a New Investigator Salary Award from the Arthritis Society (2016) and an Early Research Award from the Ontario Ministry of Research Innovation and Science (2018).

Presentation(s):

  • 0484: Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis: A Prospective Cohort Study

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 0485: Sex and Treatment-associated Outcomes in Patients with Active Psoriatic Arthritis Treated with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial

    Sunday, November 12, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 1217: Sex Differences in Perceptions of Psoriatic Arthritis Disease Impact, Management, and Physician Interactions: Results from a Global Patient Survey

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 1432: Experiences and Perspectives of Patients with Psoriatic Arthritis Participating in a Randomized Controlled Trial of Dietary Interventions

    Monday, November 13, 2023
    9:00 AM – 11:00 AM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 1687: Sex of the Patient Affects Response to Advanced Therapies in Psoriatic Arthritis: Meta-analysis of Data from Randomized Controlled Trials

    Monday, November 13, 2023
    4:00 PM – 4:10 PM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • 1689: Deep Cellular Immune Profiling in Psoriatic Arthritis Correlates with Imaging Phenotypes and Response to Targeted Advanced Therapy

    Monday, November 13, 2023
    4:30 PM – 4:40 PM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)

  • Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention

    Tuesday, November 14, 2023
    8:05 AM – 8:15 AM PT

    Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Bristol-Myers Squibb(BMS): Consultant (Terminated, April 12, 2023); Eli Lilly: Consultant (Ongoing), Grant/Research Support (Ongoing); Fresenius Kabi: Grant/Research Support (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing), Grant/Research Support (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB: Grant/Research Support (Ongoing)